Two new drugs for multiple myeloma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or did not respond to at least one prior treatment, including certain standard drugs.
- You are able to do most daily activities (performance status 2 or less).
- Your blood counts and kidney and liver function are within the study's acceptable levels.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for a few months after.
- You have not had certain other cancers, heart problems, or active infections that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This trial tests a new combination of drugs for people with multiple myeloma that has come back after previous treatment. The goal is to see if adding belantamab mafodotin to standard drugs can help control the disease better.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.